The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For ...

As 2025 draws to a close, we take a moment to look back at a series of interviews that have taken place across the year in ...

An aged helicopter fleet and inexperienced pilots from nearby Fort Belvoir had raised “widespread concern” among local pilots ...

Every once in a while, a secular trend is so obvious that everyone can see it, and that is the case with AI. Read more here.

Fundamentally, Lucid continues to face production limits that cap near-term upside despite improving deliveries. The company ...

In September, Dr. Rahm and her team embarked on an unforgettable European tour filled with speaking engagements and opportunities. A significant stop was in Pristina, Kosovo, where they hosted the ...

Cake Equity reports that to successfully fundraise in 2026, startups need clear documentation, organized records, and strong ...

Bold corporate announcements often precede real capability, leaving leaders to navigate the space between ambition and ...

Here, as selected by the Wallpaper* style team, are the 25 fashion moments that defined the zeitgeist in 2025 – from a viral ...

For Urban Company, 2025 marked a decisive shift beyond core services, as Native became a mature consumer durables play while ...

Discover Rigetti’s quantum computing growth prospects, revenue updates, and funding outlook. Learn if now is the right time ...

The Boeing 777X is set to revolutionize long-haul air travel when it eventually enters commercial service in 2027. The US ...